<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Conferences</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>ZMS-4084 shows robust antitumor efficacy in MSI-H cancer models </title>
      <description>
        <![CDATA[Werner syndrome helicase (WRN), belonging to the RecQ helicase family, represents a synthetic lethal vulnerability in MSI-H cancers, providing a strong rationale for therapeutic inhibition. Researchers from Simcere Zaiming Pharmaceutical Co. Ltd. reported the discovery and preclinical characterization of ZMS-4084, a novel WRN inhibitor.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731128</guid>
      <pubDate>Fri, 15 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731128-zms-4084-shows-robust-antitumor-efficacy-in-msi-h-cancer-models</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Cancer-cell-under-magnifying-glass.webp?t=1611092780" type="image/png" medium="image" fileSize="453785">
        <media:title type="plain">Cancer cells under magnifying glass</media:title>
      </media:content>
    </item>
    <item>
      <title>NTX-819, a novel mGlu7 NAM for psychiatric disorders</title>
      <description>
        <![CDATA[Increasing evidence supports metabotropic glutamate mGlu7 receptor as a promising target in psychiatric disorders. Neurosterix Pharma Sarl has presented data on NTX-819, a potential first-in-class, potent and selective negative allosteric modulator (NAM) of mGlu7. NTX-819 was tested in vivo in rats using behavioral tests that are relevant to disorders such as obsessive-compulsive disorder (OCD), agitation and mania/psychosis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731127</guid>
      <pubDate>Fri, 15 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731127-ntx-819-a-novel-mglu7-nam-for-psychiatric-disorders</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Psychiatry-illustration.webp?t=1710887261" type="image/jpeg" medium="image" fileSize="103707">
        <media:title type="plain">Two silhouettes with tangle, gear, spiral</media:title>
      </media:content>
    </item>
    <item>
      <title>Ensem’s ETX-929 is candidate for KRAS mutant tumors</title>
      <description>
        <![CDATA[Ensem Therapeutics Inc. has presented data for ETX-929, a small-molecule, oral pan-KRAS inhibitor with potent ON and OFF dual-state inhibitory activity for both wild-type and mutant KRAS.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731125</guid>
      <pubDate>Fri, 15 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731125-ensems-etx-929-is-candidate-for-kras-mutant-tumors</link>
    </item>
    <item>
      <title>ASGCT 2026: Directed evolution in gene therapy</title>
      <description>
        <![CDATA[Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and delivery vectors. Molecular diversification methods are increasingly sophisticated and are now accelerated by machine learning and AI tools, as showcased at the 29th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) held in Boston this week.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731119</guid>
      <pubDate>Fri, 15 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731119-asgct-2026-directed-evolution-in-gene-therapy</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/DNA-and-genome-editing.webp?t=1778858165" type="image/jpeg" medium="image" fileSize="96216">
        <media:title type="plain">DNA and genome editing illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Blueprint’s BLU-448, a CDK4 degrader for HR+/HER2- breast cancer</title>
      <description>
        <![CDATA[Work at Blueprint Medicines Corp. to identify a selective and potent CDK4 degrader led to the identification of BLU-448, with minimal activity against CDK6 for treating HR+/HER2- breast cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731102</guid>
      <pubDate>Thu, 14 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731102-blueprints-blu-448-a-cdk4-degrader-for-hr-her2-breast-cancer</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/breast-cancer-mammogram.webp?t=1617994360" type="image/png" medium="image" fileSize="409105">
        <media:title type="plain">Mammogram</media:title>
      </media:content>
    </item>
    <item>
      <title>Epirium’s 15-PGDH inhibitor IBD candidates improve disease outcomes in models</title>
      <description>
        <![CDATA[Epirium Bio Inc. has developed a series of small-molecule 15-PGDH inhibitors, the phase II-ready MF-300 and preclinical candidate MF-1305, as potential therapeutics for inflammatory bowel disease (IBD).]]>
      </description>
      <guid>http://www.bioworld.com/articles/731101</guid>
      <pubDate>Thu, 14 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731101-epiriums-15-pgdh-inhibitor-ibd-candidates-improve-disease-outcomes-in-models</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/Gastrointestinal-microbiome.webp?t=1589217172" type="image/png" medium="image" fileSize="442923">
        <media:title type="plain">Intestine</media:title>
      </media:content>
    </item>
    <item>
      <title>QW-5-70 exhibits antitumor activity in multidrug-resistant tumors</title>
      <description>
        <![CDATA[Resistance to microtubule-targeting agents such as taxanes and vinca alkaloids is often driven by drug efflux and changes in tubulin behavior. Targeting the colchicine-binding site provides an alternative strategy that may circumvent these resistance mechanisms.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731097</guid>
      <pubDate>Thu, 14 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731097-qw-5-70-exhibits-antitumor-activity-in-multidrug-resistant-tumors</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Precision-targeted-therapy-concept.webp?t=1754501515" type="image/jpeg" medium="image" fileSize="188108">
        <media:title type="plain">Precision targeted therapy concept illustrated by dart hitting bullseye of target</media:title>
      </media:content>
    </item>
    <item>
      <title>ASGCT 2026: Uncovering the mechanisms of AAV toxicity</title>
      <description>
        <![CDATA[Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other delivery strategies. Each combination is optimized for a specific cell type and indication, aiming to overcome challenges such as efficacy, specificity and toxicity. On May 13, 2026, two sessions included in the scientific symposia of the 29th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), being held in Boston this week, addressed AAV-related toxicities, which have led to fatal cases in clinical trials and remain an area for improvement in approved therapies.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731091</guid>
      <pubDate>Thu, 14 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731091-asgct-2026-uncovering-the-mechanisms-of-aav-toxicity</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Colorful-adeno-associated-viruses-AAVs.webp?t=1778776816" type="image/png" medium="image" fileSize="1832336">
        <media:title type="plain">3D illustration of adeno-associated viruses</media:title>
      </media:content>
    </item>
    <item>
      <title>Simcere’s SCR-A019 shows promise for mesothelin-expressing tumors</title>
      <description>
        <![CDATA[Mesothelin (MSLN) is a highly expressed protein in several cancer types but with limited expression in normal tissues. Simcere Pharmaceutical Co. Ltd. has presented preclinical data on the characterization of SCR-A019, an antibody-drug conjugate (ADC) carrying a topoisomerase 1 inhibitor payload and an antibody that binds to membrane Mesothelin (MSLN) over soluble MSLN and has shown robust antitumor efficacy in several cell-derived xenograft models.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731079</guid>
      <pubDate>Wed, 13 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731079-simceres-scr-a019-shows-promise-for-mesothelin-expressing-tumors</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Targeted-cancer-cell.webp?t=1748961673" type="image/jpeg" medium="image" fileSize="966728">
        <media:title type="plain">Cancer cell in the cross-hairs</media:title>
      </media:content>
    </item>
    <item>
      <title>BTX-001 enables single-dose treatment for geographic atrophy</title>
      <description>
        <![CDATA[Researchers from Beacon Therapeutics Holdings Ltd. reported the development of BTX-001, an intravitreal gene therapy designed to target the complement pathway through delivery of a C5 inhibitor.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731075</guid>
      <pubDate>Wed, 13 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731075-btx-001-enables-single-dose-treatment-for-geographic-atrophy</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Eye-and-DNA.webp?t=1621374169" type="image/png" medium="image" fileSize="619372">
        <media:title type="plain">Eye and DNA</media:title>
      </media:content>
    </item>
    <item>
      <title>HEC Pharma presents oral small-molecule PD-L1 inhibitor</title>
      <description>
        <![CDATA[HEC Pharma Co. Ltd. recently presented HEC-201625, a small-molecule PD-L1 inhibitor for cancer immunotherapy that blocks the PD-1/PD-L1 signaling pathway. HEC-201625 was tested in vitro and in vivo in MC38 syngeneic murine model, as well as in xenograft A375 and NCI-H358 models.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731017</guid>
      <pubDate>Tue, 12 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731017-hec-pharma-presents-oral-small-molecule-pd-l1-inhibitor</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Cells-receptors-inhibitors.webp?t=1667926694" type="image/png" medium="image" fileSize="1347625">
        <media:title type="plain">Concept art for cells receptors, inhibitors</media:title>
      </media:content>
    </item>
    <item>
      <title>OPGx-BEST1 restores BEST1 expression in retinal cells</title>
      <description>
        <![CDATA[Researchers at Opus Genetics Inc. reported the efficacy of OPGx-BEST1, an AVV-based gene therapy developed to deliver a functional BEST1 transgene to retinal pigment epithelium (RPE) cells to re-establish normal BEST1 expression and activity.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731014</guid>
      <pubDate>Tue, 12 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731014-opgx-best1-restores-best1-expression-in-retinal-cells</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Test-tube-dropper-research.webp?t=1588878251" type="image/png" medium="image" fileSize="320857">
        <media:title type="plain">Test tube, dropper, DNA illustration </media:title>
      </media:content>
    </item>
    <item>
      <title>JUV-161 reverses structural and functional muscle decline</title>
      <description>
        <![CDATA[At the European Congress of Endocrinology in Prague, researchers from Juvena Therapeutics Inc. presented the effects of JUV-161, a fusion protein consisting of human insulin-like growth factor 2 linked to human serum albumin, in preclinical models of myotonic dystrophy type 1 (DM1) and sarcopenia.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731013</guid>
      <pubDate>Tue, 12 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731013-juv-161-reverses-structural-and-functional-muscle-decline</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Musculoskeletal/Muscle-tissue-fiber-detail.webp?t=1709912593" type="image/jpeg" medium="image" fileSize="173605">
        <media:title type="plain">Illustration of muscle anatomy</media:title>
      </media:content>
    </item>
    <item>
      <title>Soley Therapeutics reports data on new CKAP2 modulator STX-6398</title>
      <description>
        <![CDATA[Cytoskeleton-associated protein 2 (CKAP2) is the most potent microtubule growth factor identified so far and is considered an undruggable protein, often associated with malignant progression in cancer by targeting the FAK-ERK2 signaling pathway. Using its proprietary platform, Soley Therapeutics Inc. has discovered a small molecule that modulates CKAP2 – STX-6398.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730999</guid>
      <pubDate>Mon, 11 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730999-soley-therapeutics-reports-data-on-new-ckap2-modulator-stx-6398</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Doctor-chemistry-molecule-science-research.webp?t=1778511298" type="image/jpeg" medium="image" fileSize="481427">
        <media:title type="plain">Doctor hand touching virtual molecular structure</media:title>
      </media:content>
    </item>
    <item>
      <title>Singlomics’ DXP-106 shows robust results in preclinical setting</title>
      <description>
        <![CDATA[The interleukin-1 receptor accessory protein (IL1RAP) is expressed in cancer cells within the tumor microenvironment of several cancer types and plays a role in tumor development. DXP-106 is a humanized monoclonal antibody developed by Singlomics Biopharmaceuticals Co. Ltd. that binds to a unique epitope of IL1RAP domain 2 that competes with cytokines.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730998</guid>
      <pubDate>Mon, 11 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730998-singlomics-dxp-106-shows-robust-results-in-preclinical-setting</link>
    </item>
    <item>
      <title>First long-acting, intra-articular multikinase inhibitor for OA</title>
      <description>
        <![CDATA[Researchers from Rottapharm Biotech Srl have reported preclinical efficacy data on CR-10049, a long-acting osteoarthritis-targeted multikinase inhibitor, designed to treat both osteoarthritis pain and inflammatory joint degeneration.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730997</guid>
      <pubDate>Mon, 11 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730997-first-long-acting-intra-articular-multikinase-inhibitor-for-oa</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Hand-wrist-inflammation-arthritis-joint-pain.webp?t=1771431082" type="image/jpeg" medium="image" fileSize="393611">
        <media:title type="plain">X-ray image of hand and wrist</media:title>
      </media:content>
    </item>
    <item>
      <title>Takeda’s anti-CCR8 ADC shows potent antitumor activity</title>
      <description>
        <![CDATA[Researchers from Takeda Pharmaceutical Co. Ltd. detailed the preclinical characterization of TAK-188, a first-in-class anti-CCR8 antibody-drug conjugate (ADC) designed to selectively target CCR8+ Tregs, alleviating immunosuppression in the tumor microenvironment.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730954</guid>
      <pubDate>Fri, 08 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730954-takedas-anti-ccr8-adc-shows-potent-antitumor-activity</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/TME-tumor-microenvironment-3D.webp?t=1699370810" type="image/jpeg" medium="image" fileSize="457538">
        <media:title type="plain">3D Rendering of tumor microenvironment</media:title>
      </media:content>
    </item>
    <item>
      <title>BD-200 is strong dual-targeting ADC candidate for cancer</title>
      <description>
        <![CDATA[Biolojic Design Ltd. has reported preclinical data for its antibody-drug conjugate (ADC) BD-200, developed using an AI-guided antibody engineering platform named Multibody.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730953</guid>
      <pubDate>Fri, 08 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730953-bd-200-is-strong-dual-targeting-adc-candidate-for-cancer</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Immune-antibody-drug-capsule.webp?t=1778251154" type="image/png" medium="image" fileSize="660418">
        <media:title type="plain">3D rendering of a drug capsule and flying antibodies</media:title>
      </media:content>
    </item>
    <item>
      <title>ZMS-2195 is a potent multi-RAS strategy for RAS-dependent tumors</title>
      <description>
        <![CDATA[Simcere Zaiming Pharmaceutical Co. Ltd. has detailed the discovery and preclinical characterization of ZMS-2195, a multiple-RAS inhibitor designed to prevent both mutant and wild-type forms of KRAS, NRAS and HRAS from binding to the RAS-binding domain (RBD) of RAF, which is required to activate downstream MAPK signaling.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730936</guid>
      <pubDate>Thu, 07 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730936-zms-2195-is-a-potent-multi-ras-strategy-for-ras-dependent-tumors</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/RAS-protein.webp?t=1681852766" type="image/png" medium="image" fileSize="402873">
        <media:title type="plain">RAS protein</media:title>
      </media:content>
    </item>
    <item>
      <title>Biosion’s BSI-737 exerts strong antitumor activity</title>
      <description>
        <![CDATA[Biosion Inc. recently presented preclinical data describing their B7H3/PD-L1 bispecific antibody-drug conjugate (ADC) BSI-737 for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730935</guid>
      <pubDate>Thu, 07 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730935-biosions-bsi-737-exerts-strong-antitumor-activity</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Cancer-cell-target-destroy.webp?t=1731081970" type="image/jpeg" medium="image" fileSize="520172">
        <media:title type="plain">Illustration of cancer cell in crosshairs being destroyed</media:title>
      </media:content>
    </item>
    <item>
      <title>PLX-61639 shows efficacy in SMARCA4-mutant tumors</title>
      <description>
        <![CDATA[Researchers from Plexium Inc. presented preclinical efficacy data for PLX-61639, a SMARCA2-selective degrader, in SMARCA4-mutant tumor models.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730933</guid>
      <pubDate>Thu, 07 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730933-plx-61639-shows-efficacy-in-smarca4-mutant-tumors</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/molecular-science-research-art-2.webp?t=1749649165" type="image/jpeg" medium="image" fileSize="145862">
        <media:title type="plain">Art concept for molecular glue degradation</media:title>
      </media:content>
    </item>
    <item>
      <title>Kymera’s IRF5 degrader shows potential in IBD treatment</title>
      <description>
        <![CDATA[At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5 degrader, in models of IBD.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730907</guid>
      <pubDate>Wed, 06 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730907-kymeras-irf5-degrader-shows-potential-in-ibd-treatment</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/Gastrointestinal-inflammatory-bowel-disease-IBD-Crohn.webp?t=1706553250" type="image/jpeg" medium="image" fileSize="247467">
        <media:title type="plain">Art concept for inflammation in the intestines</media:title>
      </media:content>
    </item>
    <item>
      <title>Bio Korea 2026 kicks off with spotlight on oligonucleotides</title>
      <description>
        <![CDATA[Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and the promise of “programmable,” precision medicine for patients, speakers at Bio Korea 2026 said April 28.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730927</guid>
      <pubDate>Tue, 05 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730927-bio-korea-2026-kicks-off-with-spotlight-on-oligonucleotides</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Researcher-antisense-oligonucleotides.webp?t=1775662140" type="image/jpeg" medium="image" fileSize="579461">
        <media:title type="plain">AI generated image for researcher developing antisense oligonucleotides</media:title>
      </media:content>
    </item>
    <item>
      <title>Bio Korea 2026: US policy risks shift to execution framework</title>
      <description>
        <![CDATA[Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies can tailor regulatory strategies early, and across the entire development cycle.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730926</guid>
      <pubDate>Tue, 05 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730926-bio-korea-2026-us-policy-risks-shift-to-execution-framework</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Misc/Strategy-compass.webp?t=1777923242" type="image/jpeg" medium="image" fileSize="113016">
        <media:title type="plain">Strategy compass</media:title>
      </media:content>
    </item>
    <item>
      <title>China’s new IIT rules could reshape early stage drug development </title>
      <description>
        <![CDATA[China’s investigator-initiated trial (IIT) system is increasingly being used to generate early human data in cell and gene therapies, and new changes that widen the pathway are expected to drive more multinational companies to conduct IITs in China, panelists said during the Chinabio Partnering Forum in Shanghai April 28-29.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730924</guid>
      <pubDate>Tue, 05 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730924-chinas-new-iit-rules-could-reshape-early-stage-drug-development</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Digital-health-DNA-gene-therapy-research.webp?t=1686951391" type="image/jpeg" medium="image" fileSize="229766">
        <media:title type="plain">Art concept for gene therapy research</media:title>
      </media:content>
    </item>
    <item>
      <title>RCT-1213 has strong activity in TM4SF5-expressing tumors</title>
      <description>
        <![CDATA[Tumors with strong immunosuppressive microenvironments such as microsatellite-stable colorectal cancer (MSS-CRC) remain unresponsive to immune checkpoint blockade therapy, with <20% of gastrointestinal tumors responding to therapy.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730886</guid>
      <pubDate>Tue, 05 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730886-rct-1213-has-strong-activity-in-tm4sf5-expressing-tumors</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Monoclonal-antibody-cancer-treatment.webp?t=1748961674" type="image/jpeg" medium="image" fileSize="278791">
        <media:title type="plain">Art concept for monoclonal antibody cancer treatment</media:title>
      </media:content>
    </item>
    <item>
      <title>FX-111 targets persistent androgen signaling in prostate cancer</title>
      <description>
        <![CDATA[Researchers from Flare Therapeutics Inc. presented the preclinical profile of FX-111, a selective active androgen receptor (ARON) degrader, in models of prostate cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730885</guid>
      <pubDate>Tue, 05 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730885-fx-111-targets-persistent-androgen-signaling-in-prostate-cancer</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Cancer-prostate-illustration.webp?t=1721838477" type="image/jpeg" medium="image" fileSize="115372">
        <media:title type="plain">3D illustration showing presence of tumor inside prostate gland </media:title>
      </media:content>
    </item>
    <item>
      <title>Bio Korea 2026: US policy risks shift to execution framework</title>
      <description>
        <![CDATA[Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies can tailor regulatory strategies early, and across the entire development cycle.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730835</guid>
      <pubDate>Mon, 04 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730835-bio-korea-2026-us-policy-risks-shift-to-execution-framework</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Misc/Strategy-compass.webp?t=1777923242" type="image/jpeg" medium="image" fileSize="113016">
        <media:title type="plain">Strategy compass</media:title>
      </media:content>
    </item>
    <item>
      <title>E-688 potent toward B7-H3-expressing tumors</title>
      <description>
        <![CDATA[Hypersialylation in tumor cells is a potent mechanism of tumor immune evasion, pushing cancer progression by suppressing both innate and adaptive antitumor immunity. Shanghai Henlius Biotech Inc. has developed an engineered human sialidase enzyme fused to an anti-B7-H3 nanobody, named E-688 or HLX-316, that improves tumor desialylation, durability and efficacy both in vitro and in vivo, while maintaining a safe profile.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730817</guid>
      <pubDate>Mon, 04 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730817-e-688-potent-toward-b7-h3-expressing-tumors</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Cancer-cell-tumor-target.webp?t=1692022386" type="image/jpeg" medium="image" fileSize="543788">
        <media:title type="plain">3D illustration of cancer in crosshairs</media:title>
      </media:content>
    </item>
    <item>
      <title>METTL3 inhibitor EP-102 shows broad antitumor activity</title>
      <description>
        <![CDATA[Researchers at Epics Therapeutics SA reported preclinical findings on EP-102, a METTL3 inhibitor, in models of pancreatic adenocarcinoma (PDAC).]]>
      </description>
      <guid>http://www.bioworld.com/articles/730815</guid>
      <pubDate>Mon, 04 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730815-mettl3-inhibitor-ep-102-shows-broad-antitumor-activity</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/3D-illustration-of-pancreatic-cancer.webp?t=1738336763" type="image/jpeg" medium="image" fileSize="318760">
        <media:title type="plain">3D illustration of pancreatic cancer</media:title>
      </media:content>
    </item>
  </channel>
</rss>
